CAMBRIDGE, Mass., May 6, 2026
Clear Scientific Inc., a clinical-stage biopharmaceutical company developing innovative therapies for acute drug intoxication, has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its lead investigational therapy CS-1103 for the treatment of acute fentanyl intoxication. The regulatory milestone highlights growing interest in novel approaches to address the escalating opioid crisis and accelerate the development of therapies targeting life-threatening drug overdose emergencies.
The FDA’s Fast Track program is designed to facilitate the development and expedite the review of investigational medicines intended to treat serious conditions while addressing significant unmet medical needs. Clear Scientific stated that the designation could help accelerate clinical development timelines and improve collaboration with the FDA as the company advances CS-1103 toward later-stage clinical trials.
CS-1103 Designed to Reverse Fentanyl Intoxication
According to Clear Scientific, CS-1103 is a first-in-class injectable small molecule therapeutic engineered to rapidly bind and encapsulate intoxicants circulating in the bloodstream. In preclinical studies, the therapy demonstrated the ability to neutralize toxic drug effects while accelerating elimination of intoxicants through urinary clearance, potentially reducing the risk of continued overdose complications and recurrent respiratory depression.
The company explained that CS-1103 is being developed specifically to address significant limitations associated with current opioid overdose management approaches. Existing emergency interventions such as naloxone can temporarily reverse opioid overdose symptoms, but many patients remain vulnerable to renarcotization, a dangerous recurrence of overdose symptoms after initial treatment. Clear Scientific believes CS-1103 may provide a more comprehensive therapeutic strategy by actively removing opioids from the body instead of only temporarily blocking receptor activity.
Advertisement
Clear Scientific confirmed that the therapy demonstrated a favorable safety and tolerability profile during a Phase 1 clinical trial, where healthy participants received clinically relevant dosing levels. Based on those findings, the company plans to initiate Phase 2 clinical trials for fentanyl intoxication in June 2026, representing a major advancement in the clinical development of novel overdose reversal therapies.
FDA Fast Track Status Supports Accelerated Development
Clear Scientific CEO Shekar Shetty described the FDA Fast Track designation as an important milestone for the company and emphasized the urgent need for more effective overdose and detoxification treatments in response to the rapidly worsening fentanyl epidemic. The company stated that CS-1103 could potentially improve patient stabilization during overdose emergencies while also supporting safer transition into addiction treatment programs such as buprenorphine therapy.
By rapidly clearing opioids from the bloodstream, the investigational therapy may help reduce the risk of delayed overdose complications and improve outcomes in emergency care settings. The company noted that the FDA Fast Track designation may enable more frequent interactions with regulators and provide opportunities for accelerated review processes if future clinical data continue to demonstrate therapeutic benefit.
Opioid Crisis Continues to Drive Demand for New Therapies
The announcement comes as the United States continues to face an unprecedented opioid epidemic driven largely by synthetic opioids including fentanyl. According to statistics referenced by Clear Scientific, opioids contribute to approximately 2,500 emergency department visits and 150 deaths every day in the United States. In 2024 alone, synthetic opioids were linked to more than 55,000 fatalities nationwide, underscoring the urgent need for innovative overdose treatment technologies.
The White House previously estimated that the fentanyl-driven opioid crisis cost the U.S. economy nearly $2.7 trillion in 2023, with major impacts on healthcare systems, public safety, workforce productivity, and social services across the country. Clear Scientific believes its novel therapeutic platform could introduce a new category of treatment focused on actively clearing toxic compounds from the body and reducing long-term harm associated with acute intoxication events.
Founded in 2019 by Professor George M. Whitesides of Harvard University, Clear Scientific continues to advance selective small molecule sequestrant technologies through collaborations with academic institutions and funding support from the National Institute on Drug Abuse (NIDA) and the National Institutes of Health (NIH).
Source: Clear Scientific press release
